Cd79b humanized antibody-based chimeric antigen receptor and use thereof

Abstract

Provided are a CD79b humanized antibody-based chimeric antigen receptor and use thereof. The present disclosure relates to a CD79b humanized antibody-based chimeric antigen receptor, which includes an antigen binding domain, a transmembrane domain, a co-stimulatory signaling domain, a CD3q signaling domain, and a self-destructing domain, which are sequentially connected in tandem, wherein the antigen binding domain binds to a tumor surface antigen CD79b and is a humanized scFv targeting the tumor surface antigen CD79b, and the self-destructing domain is a cysteine protease 9 domain. When the chimeric antigen receptor is applied to patients with tumors expressing the tumor-specific target CD79b, few clinical side effects are generated, the safety is high, tumor cells can be effectively killed, and the presence of CAR-T in the patients can be monitored for a long time, effectively prolonging the overall survival rate of patients.

Dependencies are inferred from the claim text.